Organisation paid for research Program year 2025 Source: CMS Open Payments

Boston Clinical Trials Inc

Neither a doctor nor a teaching hospital

Research payments

$326,933

56 payments

Through program year 2025, Boston Clinical Trials Inc is reported as receiving $326,933 in research payments, across 56 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $22,902 7
2024 Research $2,603 1
2023 Research $3,016 4
2022 Research $12,859 11
2021 Research $26,610 12
2020 Research $40,072 11
2019 Research $218,871 10

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $176,322 27 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $80,718 7 payments
  3. Ironwood Pharmaceuticals, Inc $39,543 11 payments
  4. Ultragenyx Pharmaceutical Inc. $15,728 4 payments
  5. Moderna TX, Inc. $13,794 6 payments
  6. Eli Lilly Export S.A. Puerto Rico Branch $828 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the Conquer Study $137,217 2 payments
  2. A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder $80,718 7 payments
  3. McP-103-205 $39,543 11 payments
  4. Dtx301-Cl102 $15,728 4 payments
  5. A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ?55 Years $13,794 6 payments
  6. A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $11,711 2 payments
  7. Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain $4,504 2 payments
  8. A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain $3,917 2 payments
  9. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $3,664 2 payments
  10. Randomized, Placebo Controlled, Phase 2 Clinical Trial to Evaluate Ly3556050 for the Treatment of Osteoarthritis Pain $3,625 2 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $80,718 7 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record